The cost of paediatric cystic fibrosis to the NHS in the Eastern Region  by Jarrett, J. et al.
14. Other issues S117
465 The cost of paediatric cystic ﬁbrosis to the NHS in the
Eastern Region
J. Jarrett1, R. Iles2, M. Mugford1, J. Legh-Smith2. 1Health Economics Group,
School of Medicine, Health Policy and Practice, University of East Anglia, Norwich,
Norfolk, United Kingdom; 2Dept Of Respiratory Paediatrics, Addenbrookes NHS
Trust, Cambridge, Cambridgeshire, United Kingdom
Purpose: The objective of this study is to provide a detailed account of the cost of
paediatric CF to the NHS in the Eastern Region.
Background: In a review of CF economic evaluation literature, Krauth, et al (2003)
found ﬁve Cost of Illness (COI) studies based on patient data. The authors found
that most studies underestimated healthcare costs. The studies also found that costs
are dependent on patients’ age, and grade of severity among other factors. They
found no paediatric CF care studies carried out in the UK.
Data collection methods: The analysis looks at the paediatric COI for the region in
1998 using a retrospective analysis on patient data collected in the Eastern Region
CF Database. Costs are derived from national sources.
Analysis: The viewpoint will be that of the NHS in the Eastern Region. Resource
use and costs are reported separately. Given the variance in disease severity, it is
appropriate to estimate costs of care at the individual level. An accumulation of
costs per case method is applied.
Results: The total cost of caring for 371 patients in the Eastern Region in 1998 was
approximately € 3.3 million. The mean cost per patient is estimated to be € 8,900.
Conclusion: This study provides an indication of the cost of care in the region and
can help to inform decision makers when making decisions on CF care. This study
can also provide a reference for future analysis of care in the region to determine
the most cost-effective service.
Supported by: This research was supported by a grant from the National Coordi-
nating Centre for Research Capacity Development, UK.
466 Cost development in pharmaceutical treatment of adult patients
with cystic ﬁbrosis
C.T. Baltin1, C. Smaczny1, T.O. Wagner1. 1Pneumology/Allergology, Medical
Clinic I, Frankfurt am Main, Germany
Background: Symptomatic treatment based on a sophisticated drug therapy has
become increasingly important to prolong patients’ lifespan. The resultant soaring
medication costs per patient’s life frequently collide with decreasing ﬁnancial means,
warranting a study of the economic aspects of CF therapy.
Objective: According to the guideline of the AWMF for the treatment of CF, this
study aims to present on a very accurate level the current ﬁnancial costs resulting
from the annual medication combining the medical and economical perspectives.
Furthermore, it will show the inﬂuence of cost drivers and existing deduction
contracts with health insurance schemes in Germany on the overall cost situation.
Finally, the study aims to increase transparency around cross-border ﬁnancing
arrangements in the ﬁnancially tightening pharmaceutical treatment of CF patients.
Method: Analyses are based on the prescriptions of 144 adult patients from the CF
outpatient department in Frankfurt, Germany for the entire year of 2007. Daily drug
intake of each patient was calculated and matched with corresponding prices from
the Rote Liste 2007. Classiﬁed into 7 different medication groups approximately
470 different drugs were analysed as well as their potential cost savings.
Results: Presented in poster format and oral presentation
Outlook: As a reevaluation of existing cost analyses in the CF market, the study
considers the ﬁnancial aspects of drug treatment against the objective to improve
the patients’ well-being from a more tightly focused symptomatic treatment. Taking
into account prevailing deduction contracts and already existing saving potentials
with generic drugs, this study will also provide useful information for a future
European alignment of pharmaceutical treatment for patients with CF.
467 Age speciﬁc guidelines developed for scheduled monitoring and
investigations in a pediatric CF clinic
D.K. Houlden1, L.K. Semple1, M.D. Montgomery1,2. 1Alberta Children’s
Hospital, Calgary, AB, Canada; 2University of Calgary, Calgary, AB, Canada
Cystic Fibrosis (CF) is a lifelong, complex disorder, requiring vigilant monitoring
and surveillance of multiple systems. Monitoring is achieved through regular clinic
visits and reassessments of physical, emotional and psychosocial health. Essential
components of the regular visits are laboratory and radiological investigations.
Ensuring that these investigations are completed, results reviewed, families advised
of results and corrective action taken, in an appropriate time frame, is a challenge.
Further, coordinating and anticipating the surveillance studies with clinic visits may
reduce the impact of CF on a families’ daily routine. Prolonged waiting periods
for speciﬁc tests/procedures and the need for monthly immunizations for infants
during RSV season are just a few examples.
The CF Clinic at the Alberta Children’s Hospital in Calgary, AB, Canada, has
addressed the need for a consistent approach to routine surveillance and monitoring.
Modeling after clinical practice in oncology, a “roadmap” has been developed.
The roadmap outlines planned investigations speciﬁc to each of four age groups:
0−5 years, 6−10 yrs, 11−15 years, and 16−18 years. The roadmap outlines speciﬁc
measures recommended at each scheduled clinic visit. In addition, recommendations
to help parents increase their child’s independence for daily CF care routines are
provided. Tips to anticipate transition from the pediatric to adult CF center are also
included. Families and clinic staff have reacted positively to the introduction of
the roadmaps. Impact on resource utilization and a family satisfaction survey are
ongoing.
468 Obtaining ethics approval for a multi-centre cystic ﬁbrosis (CF)
study in Australia
T.J. Kidd1, P.T. Bye1, C. Harbour1, B.R. Rose1, G.B. Marks1, P.J. Robinson1,
S.C. Bell1. 1Australian Clonal Pseudomonas aeruginosa in CF Study Group,
Brisbane, QLD, Australia
Aim: To describe the process of Human Research Ethics Committee (HREC)
approval for a National Health and Medical Research Council (NHMRC) funded
multi-centre, non-interventional study involving persons with CF.
Methods: Review of observational data collected throughout the application and
approval process involving 18 HRECs and 18 CF-care centres in Australia between
December 2006 and January 2008.
Results: Each HREC was registered with the NHMRC and facilitated the review of
research proposals as prescribed in the National Statement on Ethical Conduct in
Human Research (2007). Twelve HRECs accepted the National Ethics Application
Form, three accepted a standard state-wide form, and three would only accept
a site speciﬁc form. Only two HRECs provided expedited review based on the
decisions made by other HRECs. Despite previous scientiﬁc peer review by the
peak medical research body, 47% of the HRECs required local scientiﬁc review
prior to consideration by the HREC. The total time taken for ﬁnal approval to be
granted ranged from 13 to 77 days (median = 46); and 7 HRECs provided approval
without revision. There where 78 clariﬁcations/comments made by HRECs; the
majority of points raised were not apparently related to ethical or scientiﬁc issues.
The process has taken 13 months to date (3 centres submission outcome pending),
13000 sheets of paper and approximately 6 months of a Research Ofﬁcer’s time to
complete.
Conclusions: Gaining multi-centre HREC approval in the Australian healthcare
setting is a costly, laborious and an uncoordinated process. This analysis highlights
an urgent need for an electronically integrated approval process whereby HRECs
will consider the ethical decisions that have been made by others.
Supported by: NHMRC.
